Eurobio Scientific: GenDx reduces organ matching time to 3 hours
17 Ottobre 2023 - 5:40PM
Eurobio Scientific: GenDx reduces organ matching time to 3 hours
Eurobio Scientific: GenDx reduces organ
matching time to 3 hours
- Launch of NGS-Turbo, a
unique test to match organs on Oxford Nanopore Technologies
sequencing devices
- A valuable technological
partnership with Oxford Nanopore Technologies
- A significant advance in
HLA typing
Paris, 17th
October 2023 – 5:40 pm
Eurobio Scientific
(FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME eligible), a
leading French group in in vitro specialty medical diagnostics and
life sciences, today announces the launch by its GenDx subsidiary
of their newly developed product, NGS-Turbo®, designed for HLA
typing using Oxford Nanopore Technologies sequencing devices, for
Research Use Only (RUO). NGS-Turbo represents a significant leap
forward in the field of HLA typing, offering unparalleled speed and
efficiency when time is of the essence.
With the release of this new product, GenDx
continues to push the boundaries of innovation in the field of HLA
typing, and NGS-Turbo demonstrates their commitment to providing
cutting-edge solutions for the transplantation community.
NGS-Turbo is characterized by its exceptional
turnaround time, providing high-resolution HLA typing results in as
little as three hours, from blood sample to the final result.
Maarten Penning, PhD, PhD, General Manager of
GenDx, declares: “Our collaboration with Oxford Nanopore has
led to the development of an assay that not only seamlessly
integrates with their platform but also excels in speed and
user-friendliness. The overwhelmingly positive feedback received
during the early access program speaks volumes about the product's
potential impact.”
Denis Fortier, CEO of Eurobio Scientific, adds:
“This new product will enable us to increase our market share in
HLA typing. It also has the potential to expand the transplant
market: by reducing the compatibility test to just 3 hours, we can
envisage new possibilities for situations where existing
technologies are too slow to test high-resolution compatibility.
The launch of NGS-Turbo is further proof of the Group's strong
capacity for innovation.”
Next financial meeting2023 FY revenues: January
30, 2024, after market closes
About HLAThe Human Leukocyte
Antigen (HLA) system comprises a diverse family of genes and
allelic variants crucial for the human immune system. Precise HLA
matching between patients and donors is essential in
transplantation, as even slight differences in HLA alleles can
significantly impact transplant outcomes. HLA typing enables the
identification of specific nucleotide sequences, making it an
indispensable tool for transplantation purposes.
About Oxford Nanopore
TechnologiesOxford Nanopore Technologies’ goal is to bring
the widest benefits to society through enabling the analysis of
anything, by anyone, anywhere. The company has developed a new
generation of nanopore-based sensing technology for real-time,
high-performance, accessible and scalable analysis of DNA and RNA.
The technology is used in more than 120 countries to understand the
biology of humans and diseases such as cancer, plants, animals,
bacteria, viruses and whole environments. Oxford Nanopore
Technologies products are intended for molecular biology
applications and are not intended for diagnostic purposes.
About GenDx, a Eurobio Scientific
companyGenome Diagnostics B.V., trading as GenDx, is a
Dutch company specializing in molecular diagnostics. It focuses on
the development, production, and sale of innovative assays and
analysis software for transplantation and companion diagnostics.
GenDx offers a range of HLA sequencing-based typing strategies,
reagents, software, and custom laboratory services. GenDx Education
also provides dedicated training courses worldwide for
professionals in tissue typing, research laboratories, blood banks,
and donor registries. In October 2022, Eurobio Scientific acquired
all shares of GenDx. For more information, visit www.GenDx.com.
| About
Eurobio ScientificEurobio Scientific is a key player in
the field of specialty in vitro diagnostics. It is involved from
research to manufacturing and commercialization of diagnostic tests
in the fields of transplantation, immunology and infectious
diseases, and sells instruments and products for research
laboratories, including biotechnology and pharmaceutical companies.
Through many partnerships and a strong presence in hospitals,
Eurobio Scientific has established its own distribution network and
a portfolio of proprietary products in the molecular biology field.
The Group has approximately 290 employees and four production units
based in the Paris region, in Germany, in the Netherlands and in
the United States, and several affiliates based in Dorking UK,
Sissach Switzerland, Bünde Germany, Antwerp Belgium, Utrecht in The
Netherlands and Milan in Italy.Eurobio Scientific's reference
shareholder is the EurobioNext holding company which brings
together its two directors, Jean-Michel Carle and Denis Fortier,
alongside the "Pépites et Territoires" by AXA & NextStage AM
investment program, managed by NextStage AM. For more information,
please visit: www.eurobio-scientific.comThe company is publicly
listed on the Euronext Growth market in ParisEuronext Growth BPI
Innovation, PEA-PME 150 and Next Biotech indices, Euronext European
Rising Tech label.Symbol: ALERS - ISIN Code: FR0013240934 -
Reuters: ALERS.PA - Bloomberg: ALERS:FP |
|
Contacts |
|
Groupe Eurobio ScientificDenis Fortier, Chairman
and CEOAnne-Sophie Hérelle, Deputy CEO Finance & ITTel. +33(0)
1 69 79 64 80 |
CalyptusMathieu CalleuxInvestors RelationsTel.
+33(1) 53 65 68 68 - eurobio-scientific@calyptus.net |
- 231009_EUROBIO_GenDx_NGS_ENok
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Nov 2023 a Nov 2024
